ATH — Alterity Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- AU$12.61m
- AU$0.55m
- AU$0.02m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.109 | 0.017 | 0.021 | 0.003 | 0.016 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 12.8 | 13.8 | 15.2 | 16 | 14.6 |
Operating Profit | -12.7 | -13.8 | -15.2 | -16 | -14.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.3 | -13.5 | -15.3 | -12.8 | -13.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.3 | -13.5 | -15.3 | -12.8 | -13.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -12.3 | -13.5 | -15.3 | -12.8 | -13.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -12.3 | -13.5 | -15.3 | -12.8 | -13.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.02 | -0.015 | -0.009 | -0.005 | -0.006 |